Share-based Payment Arrangement, Expense in USD of RELMADA THERAPEUTICS, INC. from Q3 2013 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Relmada Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and change rate from Q3 2013 to Q1 2025.
  • Relmada Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $4.48M, a 46% decline year-over-year.
  • Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $30.2M, a 31.1% decline from 2023.
  • Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $43.8M, a 0.87% decline from 2022.
  • Relmada Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $44.2M, a 9.14% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

RELMADA THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $4.48M -$3.82M -46% 01 Jan 2025 31 Mar 2025 10-Q 12 May 2025
Q1 2024 $8.3M -$3.06M -26.9% 01 Jan 2024 31 Mar 2024 10-Q 12 May 2025
Q1 2023 $11.4M -$576K -4.83% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024
Q1 2022 $11.9M +$6.08M +104% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023
Q1 2021 $5.85M +$812K +16.1% 01 Jan 2021 31 Mar 2021 10-Q 05 May 2022
Q1 2020 $5.04M +$4.64M +1177% 01 Jan 2020 31 Mar 2020 10-Q 12 May 2021
Q1 2019 $395K 01 Jan 2019 31 Mar 2019 10-Q 15 May 2020
Q3 2018 $153K +$83.9K +122% 01 Jul 2018 30 Sep 2018 10-Q 13 Nov 2018
Q3 2017 $601K $68.9K -$103K -60% 01 Jul 2017 30 Sep 2017 10-Q 13 Nov 2018
Q2 2017 $705K $292K -$67.5K -18.8% 01 Apr 2017 30 Jun 2017 10-K 28 Sep 2018
Q1 2017 $772K $109K -$168K -60.8% 01 Jan 2017 31 Mar 2017 10-Q 15 May 2017
Q4 2016 $940K $132K -$156K -54.1% 01 Oct 2016 31 Dec 2016 10-Q 10 Feb 2017
Q3 2016 $1.1M $172K -$111K -39.3% 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017
Q2 2016 $1.21M $359K +$163K +82.5% 01 Apr 2016 30 Jun 2016 10-K 28 Sep 2017
Q1 2016 $1.04M $277K +$32.7K +13.4% 01 Jan 2016 31 Mar 2016 10-Q 15 May 2017
Q4 2015 $1.01M $288K +$89.4K +45.1% 01 Oct 2015 31 Dec 2015 10-Q 10 Feb 2017
Q3 2015 $923K $284K +$126K +79.4% 01 Jul 2015 30 Sep 2015 10-Q 10 Nov 2016
Q2 2015 $797K $197K 01 Apr 2015 30 Jun 2015 10-K 09 Sep 2016
Q1 2015 $244K +$178K +273% 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016
Q4 2014 $198K 01 Oct 2014 31 Dec 2014 10-Q 05 Feb 2016
Q3 2014 $158K +$158K 01 Jul 2014 30 Sep 2014 10-Q 06 Nov 2015
Q1 2014 $65.4K 01 Jan 2014 31 Mar 2014 10-Q 15 May 2015
Q3 2013 $0 01 Jul 2013 30 Sep 2013 10-Q 07 Nov 2014

RELMADA THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $30.2M -$13.6M -31.1% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025
2023 $43.8M -$384K -0.87% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025
2022 $44.2M +$3.7M +9.14% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024
2021 $40.5M +$19.7M +94.9% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023
2020 $20.8M +$17.6M +556% 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
2019 $3.17M +$2.65M +511% 01 Jan 2019 31 Dec 2019 10-K 24 Mar 2021
2018 $518K -$187K -26.5% 01 Jul 2017 30 Jun 2018 10-KT 26 Mar 2020
2017 $705K -$503K -41.6% 01 Jul 2016 30 Jun 2017 10-K 28 Sep 2018
2016 $1.21M +$410K +51.5% 01 Jul 2015 30 Jun 2016 10-K 28 Sep 2017
2015 $797K 01 Jul 2014 30 Jun 2015 10-K 09 Sep 2016
2013 $382K 01 Jan 2013 31 Dec 2013 10-K 11 Sep 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.